At Xontogeny, we believe there is no better return on investment than the path from preclinical signal to the value-inflection from a successful Phase 2 proof-of-concept study. Xontogeny was founded to produce the most significant returns on investment by efficiently and optimally increasing the rates in which drug technology is successfully advanced.

Do you find the potential for outsized returns that come with successful seed and early investment very attractive?

Does the industry’s batting average in drug development scare you away from investment in preclinical and early clinical stage assets?

Are you seeking a more efficient R&D model that will minimize the investment capital risk while focusing on the truly critical activities that will lead to better returns and larger value inflections with early stage investments?

Please inquire at investors@xontogeny.com to find out how you can get involved.